0001104659-20-007262.txt : 20200127
0001104659-20-007262.hdr.sgml : 20200127
20200127190344
ACCESSION NUMBER: 0001104659-20-007262
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200123
FILED AS OF DATE: 20200127
DATE AS OF CHANGE: 20200127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Campagna Jason
CENTRAL INDEX KEY: 0001793338
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35668
FILM NUMBER: 20551025
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 10 HUDSON YARDS, FLOOR 37
CITY: NEW YORK
STATE: NY
ZIP: 10001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001270073
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223868459
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 HUDSON YARDS, 37TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10001
BUSINESS PHONE: 646-747-1000
MAIL ADDRESS:
STREET 1: 10 HUDSON YARDS, 37TH FLOOR
CITY: New York
STATE: NY
ZIP: 10001
FORMER COMPANY:
FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031113
4
1
tm205922d3_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-01-23
0
0001270073
INTERCEPT PHARMACEUTICALS, INC.
ICPT
0001793338
Campagna Jason
C/O INTERCEPT PHARMACEUTICALS, INC.
10 HUDSON YARDS, FLOOR 37
NEW YORK
NY
10001
0
1
0
0
Chief Medical Officer
Common Stock
2020-01-23
4
A
0
4200
0
A
10503
D
Option to Purchase Common Stock
99.66
2020-01-23
4
A
0
6900
0
A
2030-01-23
Common Stock
6900
6900
D
Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.
/s/ Mark Pruzanski, as attorney-in-fact
2020-01-27